Literature DB >> 17245619

Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child.

Alvaro Lassaletta1, Pilar Perez-Olleros, Cristina Scaglione, Sara Sirvent, Inma De Prada, Antonio Perez-Martinez, Alberto Ruiz-Hernandez, Luis Madero.   

Abstract

Ependymoma is the third most common CNS tumor in children. Neuraxis dissemination at the time of diagnosis is rare and occurs in fewer than 10% of patients. Recent advances in neuroimaging, neurosurgery, and radiation therapy have improved disease control and functional outcomes for children with ependymoma. However, children under the age of 3 years with ependymoma and leptomeningeal spread historically have had worse outcomes. It is not clear if age alone, or a combination of risk factors such us unfavorable location, which may prevent gross total resection, and withholding radiation therapy may have contributed to poor outcomes in younger age groups. The reason for attempting GTR is based on results from retrospective and prospective studies, where the most important prognostic factor is extent of resection. These patients are not candidates for craniospinal irradiation. Therefore, new therapeutic approaches must be attempted. This is a case report of a posterior fossa ependymoma with leptomeningeal dissemination in a two-year-old child, successfully treated with dose intensive chemotherapy and intrathecal liposomal cytarabine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245619     DOI: 10.1007/s11060-006-9327-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  15 in total

1.  CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis.

Authors:  Igor M Poltinnikov; Thomas E Merchant
Journal:  Pediatr Blood Cancer       Date:  2006-08       Impact factor: 3.167

2.  Concomitant conus medullaris ependymoma and filum terminale lipoma: case report.

Authors:  Gary L Gallia; Peter C Burger; Ian Suk; Carlos A Bagley; Jean-Paul Wolinsky; Ira M Garonzik; Ziya L Gokaslan
Journal:  Neurosurgery       Date:  2006-06       Impact factor: 4.654

3.  Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.

Authors:  Juan-Manuel Sancho; Josep-Maria Ribera; Maria-José Romero; Victoria Martín-Reina; Pilar Giraldo; Elena Ruiz
Journal:  Haematologica       Date:  2006-03       Impact factor: 9.941

4.  The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.

Authors:  Daniel R Fassett; James Pingree; John R W Kestle
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

5.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

Authors:  M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

Review 6.  Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.

Authors:  Antonio Rueda Domínguez; David Olmos Hidalgo; Ruth Viciana Garrido; Esperanza Torres Sánchez
Journal:  Clin Transl Oncol       Date:  2005-07       Impact factor: 3.405

Review 7.  Clinical pharmacology of encapsulated sustained-release cytarabine.

Authors:  D J Murry; S M Blaney
Journal:  Ann Pharmacother       Date:  2000-10       Impact factor: 3.154

Review 8.  Ependymoma: new therapeutic approaches including radiation and chemotherapy.

Authors:  Thomas E Merchant; Maryam Fouladi
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

9.  Massive intratumoral hemorrhage of ependymoma of the fourth ventricle.

Authors:  Masaru Honda; Gohei So; Makio Kaminogo; Kuniko Abe; Izumi Nagata
Journal:  Childs Nerv Syst       Date:  2005-02-03       Impact factor: 1.475

10.  Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma.

Authors:  Thomas E Merchant; Raymond K Mulhern; Matthew J Krasin; Larry E Kun; Tani Williams; Chenghong Li; Xiaoping Xiong; Raja B Khan; Robert H Lustig; Frederick A Boop; Robert A Sanford
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

View more
  9 in total

Review 1.  Salvage chemotherapy for metastatic and recurrent ependymoma of childhood.

Authors:  Eric Bouffet; Michael Capra; Ute Bartels
Journal:  Childs Nerv Syst       Date:  2009-04-10       Impact factor: 1.475

2.  Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence.

Authors:  Ryuta Saito; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2010-02-26       Impact factor: 3.042

3.  Liposomal cytarabine for central nervous system embryonal tumors in children and young adults.

Authors:  Sonia Partap; Patricia A Murphy; Hannes Vogel; Patrick D Barnes; Michael S B Edwards; Paul G Fisher
Journal:  J Neurooncol       Date:  2010-09-22       Impact factor: 4.130

4.  Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement.

Authors:  A Navajas; A Lassaletta; A Morales; B López-Ibor; C Sábado; C Moscardó; E Mateos; J Molina; M Sagaseta; A Sastre
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 5.  Low-grade ependymoma with late metastasis: autopsy case study and literature review.

Authors:  Wael Alshaya; Vivek Mehta; Beverly A Wilson; Susan Chafe; Keith E Aronyk; Jian-Qiang Lu
Journal:  Childs Nerv Syst       Date:  2015-05-10       Impact factor: 1.475

6.  Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.

Authors:  Alvaro Lassaletta; Blanca Lopez-Ibor; Elena Mateos; Marta Gonzalez-Vicent; Antonio Perez-Martinez; Julian Sevilla; Miguel A Diaz; Luis Madero
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

7.  Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.

Authors:  Maria Grazia Passarin; Giuseppe Moretto; Anna Maria Musso; Sarah Ottaviani; Barbara Masotto; Claudio Ghimenton; Paolo Iuzzolino; Ebba Buffone; Roberta Rudà; Riccardo Soffietti; Emanuela Vattemi; Rebecca Pedersini
Journal:  J Neurooncol       Date:  2009-10-31       Impact factor: 4.130

8.  Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.

Authors:  Kristian W Pajtler; Stephan Tippelt; Nele Siegler; Stefanie Reichling; Martina Zimmermann; Ruth Mikasch; Udo Bode; Astrid Gnekow; Torsten Pietsch; Martin Benesch; Stefan Rutkowski; Gudrun Fleischhack
Journal:  J Neurooncol       Date:  2016-05-04       Impact factor: 4.130

Review 9.  Management strategies for recurrent ependymoma in the paediatric population.

Authors:  M Sangra; N Thorp; P May; B Pizer; C Mallucci
Journal:  Childs Nerv Syst       Date:  2009-05-30       Impact factor: 1.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.